Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Interpace Diag Group (IDXG)

Interpace Diag Group (IDXG)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,401
  • Shares Outstanding, K 38,196
  • Annual Sales, $ 21,900 K
  • Annual Income, $ -12,190 K
  • 60-Month Beta 2.16
  • Price/Sales 0.76
  • Price/Cash Flow N/A
  • Price/Book 0.71
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.53
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/12/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.10
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.38 +18.11%
on 11/26/19
0.81 -44.66%
on 11/13/19
-0.30 (-40.00%)
since 11/08/19
3-Month
0.38 +18.11%
on 11/26/19
0.90 -50.00%
on 09/16/19
-0.29 (-39.20%)
since 09/09/19
52-Week
0.38 +18.11%
on 11/26/19
1.12 -59.82%
on 01/22/19
-0.56 (-55.45%)
since 12/07/18

Most Recent Stories

More News
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China

Further Strengthens Business Development Team with Key Hire

IDXG : 0.45 (+4.80%)
Interpace Biosciences Launches New Corporate Website

Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, "Interpace.com". Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented...

IDXG : 0.45 (+4.80%)
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results

Third Quarter Revenue Grew 34% Over the Prior Year's Quarter and 25% Year to Date

IDXG : 0.45 (+4.80%)
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019

Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss...

IDXG : 0.45 (+4.80%)
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility

Clinical Data Highlights the Utility of ThyGeNEXT and ThyraMIR

IDXG : 0.45 (+4.80%)
Interpace to Present Data at the ATA Annual Meeting

Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89 Annual Meeting of the American Thyroid Association (ATA), being...

IDXG : 0.45 (+4.80%)
Cancer Genetics, Inc. Announces Strategic Transactions

Note Payment Received from Interpace Diagnostics Group, Inc.

CGIX : 6.83 (-2.29%)
IDXG : 0.45 (+4.80%)
Interpace to Present at the American College of Gastroenterology Conference

Interpace hosts 2 Annual Fellow Programs

IDXG : 0.45 (+4.80%)
Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...

CGIX : 6.83 (-2.29%)
IDXG : 0.45 (+4.80%)
Interpace Named to 'Most Admired Companies' List

Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review's...

IDXG : 0.45 (+4.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade IDXG with:

Business Summary

Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey.

See More

Key Turning Points

2nd Resistance Point 0.48
1st Resistance Point 0.46
Last Price 0.45
1st Support Level 0.43
2nd Support Level 0.42

See More

52-Week High 1.12
Fibonacci 61.8% 0.84
Fibonacci 50% 0.75
Fibonacci 38.2% 0.66
Last Price 0.45
52-Week Low 0.38

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar